Story perspectives

Lilly’s Gene Editor Slashes LDL-C 62% in Phase 1b

5/26/2026

Summary

Lilly Cuts LDL

Eli Lilly reported that its base editor VERVE-102 lowered LDL-C by up to 62% in a Phase 1b study using a 1 mg/kg dose.
Lower doses also reduced LDL-C, though with weaker magnitude.
A single infusion cut PCSK9 levels by 51% to 88%.
Lilly will start a Phase 2 trial before the end of 2026.
Analysts noted June 2025 $1.3 billion Verve purchase and questioned gene-editing market need versus Merck’s enlicitide and Amgen’s Repatha.

Summary

Lilly Trial Halt

Regulators could halt VERVE-102 trials if DNA edits or liver toxicity appear, given permanent genome alteration.
Phase 1b lacked a long-term comparison group, limiting rare heart-event assessment.
VERVE-102’s market success will hinge on long-term safety and cost-effectiveness versus PCSK9 inhibitors, raising ethical questions about irreversible genome changes, underscoring safety concerns after earlier gene-editing caused inflammation from lipid-nanoparticle delivery, and prompting Eli Lilly to also advance VERVE-201 targeting a different cardiovascular gene.

Summary

Lilly unveils VERVE-102

Eli Lilly disclosed Phase 1 results for VERVE-102 on Monday, the first public communication since acquiring Verve Therapeutics.
The firm created an encrypted Signal tip line (JasonMast.77) for VERVE-102 leaks and bought Verve Therapeutics for roughly $1 billion, a figure different from the later-reported $1.3 billion valuation.
Executives framed heart disease as the world’s leading killer and promoted a one-time dose as an adherence aid for patients who have trouble staying on cholesterol medicines.

1 of 3

Lilly Cuts LDL

Eli Lilly reported that its base editor VERVE-102 lowered LDL-C by up to 62% in a Phase 1b study using a 1 mg/kg dose.
Lower doses also reduced LDL-C, though with weaker magnitude.
A single infusion cut PCSK9 levels by 51% to 88%.
Lilly will start a Phase 2 trial before the end of 2026.
Analysts noted June 2025 $1.3 billion Verve purchase and questioned gene-editing market need versus Merck’s enlicitide and Amgen’s Repatha.

1 / 3